Predictive Cancer Biomarkers: Current Practice and Future Challenges

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F19%3A73594731" target="_blank" >RIV/61989592:15110/19:73594731 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Predictive Cancer Biomarkers: Current Practice and Future Challenges

Popis výsledku v původním jazyce

Personalized cancer treatment became a standard approach in the treatment of human cancers in twenty-first century. Among predictive cancer biomarkers, the estrogen and progesterone receptors (ER, PR) have the longest history: they have been used in the clinic to predict responses to endocrine therapy in breast cancer for over 40 years. Similarly, the HER2 receptor status measurements have been used clinically to predict responsiveness to trastuzumab (Herceptin) in breast cancers for over 15 years. The success of the personalized approach in oncology has multiple determinants. Among others, most prominent is the nature of the disease, which is multifactorial in principle and requires patient stratification in order to select the most appropriate treatment to achieve meaningful therapeutic benefit and substantiate the relative high cost of therapy.

Název v anglickém jazyce

Predictive Cancer Biomarkers: Current Practice and Future Challenges

Popis výsledku anglicky

Personalized cancer treatment became a standard approach in the treatment of human cancers in twenty-first century. Among predictive cancer biomarkers, the estrogen and progesterone receptors (ER, PR) have the longest history: they have been used in the clinic to predict responses to endocrine therapy in breast cancer for over 40 years. Similarly, the HER2 receptor status measurements have been used clinically to predict responsiveness to trastuzumab (Herceptin) in breast cancers for over 15 years. The success of the personalized approach in oncology has multiple determinants. Among others, most prominent is the nature of the disease, which is multifactorial in principle and requires patient stratification in order to select the most appropriate treatment to achieve meaningful therapeutic benefit and substantiate the relative high cost of therapy.

Druh

C - Kapitola v odborné knize

CEP obor

—

OECD FORD obor

10608 - Biochemistry and molecular biology

Projekt

<a href="/cs/project/LO1304" target="_blank" >LO1304: Podpora udržitelnosti Ústavu molekulární a translační medicíny</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2019

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název knihy nebo sborníku

Handbook of Biomarkers and Precision Medicine

ISBN

978-1-4987-6258-8

Počet stran výsledku

11

Strana od-do

383-393

Počet stran knihy

631

Název nakladatele

CRC Press

Místo vydání

Boca Raton (FL)

Kód UT WoS kapitoly

—